RESEARCH
www.commprac.com
ISSN 1462 2815

CANCER EPIGENOMICS: UNRAVELLING THE COMPLEXITY OF EPIGENETIC ALTERATIONS IN CANCER PROGRESSION

Sneha Sree S [1], Vinodhini Priyanka Radhakrishnan [2] and Murugesan K [3]*

[1,2,3] Department of Oral and Maxillofacial Surgery, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Science (SIMATS), Saveetha University, Poonamalle High Road, Velappanchavadi, Chennai.
*Corresponding Author Email: dr.mkm70@gmail.com

DOI: 10.5281/zenodo.10977020

Abstract

Cancer Epigenomics delves into the intricate landscape of epigenetic alterations driving cancer progression. Epigenetics, the study of inheritable changes in gene expression without alterations in the DNA sequence, encompasses DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA regulation. Dysregulation of these mechanisms disrupts normal gene expression patterns, contributing to oncogenic transformation and fueling cancer progression. DNA methylation involves the addition of methyl groups to CpG dinucleotides, leading to transcriptional silencing of tumor suppressor genes or activation of oncogenes. Histone modifications, such as acetylation and methylation, alter chromatin structure, influencing gene accessibility and expression. Chromatin remodeling complexes dynamically regulate chromatin structure, impacting gene transcription and cellular function. Non-coding RNAs, including microRNAs and long non-coding RNAs, participate in post-transcriptional gene regulation, influencing key cellular processes in cancer biology. Understanding the complex interplay between epigenetic alterations and cancer biology holds promise for the development of novel therapeutic strategies. Targeting epigenetic regulators, such as DNA methyltransferases and histone deacetylases, with small molecule inhibitors or RNA-based therapeutics offers potential for cancer treatment. Additionally, non-coding RNAs represent attractive targets for cancer therapy, with emerging RNA-based therapeutics showing promise in preclinical models.

Keywords: Cancer, Epigenomics, Epigenetic Alterations, Gene Expression, DNA Methylation, Histone Modifications, Chromatin Remodelling, Non-coding RNAs, Oncogenic Transformation.

INTRODUCTION

Cancer poses a significant global health challenge, marked by its multifaceted nature of uncontrolled cell growth and proliferation. While genetic mutations have traditionally been acknowledged as key drivers of cancer development, the field of epigenomics has emerged to highlight the critical role of epigenetic alterations in cancer progression (Chandraprasad, Dey et al. 2022). This review seeks to navigate the complex terrain of cancer epigenomics, delving into the mechanisms underpinning epigenetic dysregulation, its significant impact on gene expression and cellular behavior, and the promising therapeutic strategies it unveils. Epigenetics, the study of heritable changes in gene expression that occur without alterations in the DNA sequence, has revolutionized our understanding of cancer biology. These modifications, including DNA methylation (Kulis and Esteller 2010, Skvortsova, Stirzaker et al. 2019), histone modifications, chromatin remodeling, and non-coding RNA regulation, intricately regulate gene expression, enabling cells to dynamically respond to internal and external stimuli. Dysregulation of these epigenetic mechanisms can disrupt normal gene expression patterns, driving oncogenic transformation and fueling cancer progression. The impact of epigenetic alterations on gene expression and cellular behavior in cancer is profound. Dysregulation of tumor suppressor genes and oncogenes disrupts key signaling pathways involved in cell proliferation, survival, and

metastasis. Moreover, epigenetic changes contribute to tumor heterogeneity, allowing cancer cells to adapt to changing environments and evade therapeutic interventions (Majid, Dar et al. 2010, Cao, Ribeiro et al. 2012). Therapeutically, targeting epigenetic regulators holds promise as a novel approach to cancer treatment. Epigenetic drugs, such as DNA methyltransferase and histone deacetylase inhibitors, have shown efficacy in preclinical and clinical studies, offering potential therapeutic benefits either alone or in combination with conventional chemotherapy or immunotherapy. Additionally, non-coding RNAs represent attractive targets for cancer therapy, with emerging RNA-based therapeutics showing promise in preclinical models (Maini, Breedveld et al. 1998, Aggarwal and Harikumar 2009).

Understanding Epigenetic Dysregulation

Epigenetics refers to heritable changes in gene expression that occur without alterations in the DNA sequence. These modifications, which include DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA-mediated regulation, exert precise control over gene transcription, allowing cells to dynamically respond to internal and external cues. Dysregulation of these epigenetic mechanisms can disrupt normal gene expression patterns, precipitating oncogenic transformation and fueling cancer progression (Yang, Tao et al. 2015, Statello, Guo et al. 2021, Soutschek and Schratt 2023).

DNA Methylation

DNA methylation, the addition of methyl groups to specific cytosine residues within CpG dinucleotides, is a prominent epigenetic modification implicated in cancer. Hypermethylation of CpG islands located in gene promoter regions can lead to transcriptional silencing of tumor suppressor genes, while hypomethylation of gene bodies and regulatory elements may promote oncogene activation. Aberrant DNA methylation patterns have been observed across various cancer types, contributing to the malignant phenotype (Hatziapostolou and Iliopoulos 2011, Van Tongelen, Loriot et al. 2017).

DNA methylation, a well-studied epigenetic modification, involves the addition of methyl groups to specific cytosine residues within CpG dinucleotides. Hypermethylation of gene promoter regions can silence tumor suppressor genes, while hypomethylation of regulatory elements may activate oncogenes. Similarly, histone modifications, such as acetylation, methylation, phosphorylation, and ubiquitination, play a crucial role in regulating chromatin structure and gene accessibility (Dinant, Houtsmuller et al. 2008, Chandrasekharan, Huang et al. 2009). Dysregulated histone modifications can alter the expression of genes involved in key cellular processes, contributing to cancer development. Chromatin remodeling complexes actively modify chromatin structure to regulate gene expression, and aberrant activity of these complexes has been implicated in oncogenesis. Furthermore, non-coding RNAs, including microRNAs and long non-coding RNAs, play important roles in post-transcriptional gene regulation. Dysregulated expression of non-coding RNAs can influence cellular phenotypes and contribute to cancer progression (Forrest and Khalil 2017).

Histone Modifications

Histone modifications, involving covalent alterations to histone proteins such as acetylation, methylation, phosphorylation, and ubiquitination, play a crucial role in

chromatin structure and gene accessibility. Dysregulated histone modifications, often mediated by aberrant activity of histone-modifying enzymes, can promote cancer development by altering the expression of genes involved in cell cycle regulation, DNA repair, and metastasis.

The interplay between different histone marks and chromatin remodeling complexes further adds complexity to the epigenetic regulation of gene expression in cancer (Alcid and Tsukiyama 2014, Ahmed, Sultana et al. 2021, Aloufi 2022).

Chromatin Remodelling

Chromatin remodeling complexes, comprised of ATP-dependent enzymes, actively modify chromatin structure to facilitate or restrict access to DNA. Perturbations in chromatin remodeling, arising from mutations or altered expression of remodeling factors, can disrupt normal gene regulation and contribute to oncogenesis. These complexes play critical roles in regulating DNA replication, DNA repair, and gene transcription, with aberrant remodeling activity being implicated in cancer initiation and progression (Alcid and Tsukiyama 2014, Anand, Bharathi et al. 2021).

Non-coding RNAs

Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), exert post-transcriptional regulatory control over gene expression. Dysregulated expression of these non-coding RNAs has been implicated in various aspects of cancer biology, including proliferation, invasion, and metastasis.

Moreover, non-coding RNAs can serve as diagnostic biomarkers and therapeutic targets, offering novel strategies for cancer management (Asselin and Rizzari 2015, Archetti, Ingala et al. 2019, Askarian, Gholami et al. 2023).

Impact on Gene Expression and Cellular Behavior

Epigenetic alterations exert profound effects on gene expression and cellular behavior in cancer. Dysregulation of tumor suppressor genes and oncogenes through DNA methylation and histone modifications can disrupt key signaling pathways involved in cell proliferation, survival, and metastasis.

Moreover, epigenetic changes contribute to tumor heterogeneity, allowing cancer cells to adapt to changing microenvironments and evade therapeutic interventions. Non-coding RNAs further contribute to the regulatory landscape of cancer, modulating gene expression programs and influencing cellular phenotypes (Conway, Herrmann et al. 2019, Dama, Melocchi et al. 2019, Brüssow 2020).

Therapeutic Implications

The elucidation of epigenetic mechanisms driving cancer progression has opened up new therapeutic avenues for cancer treatment. Epigenetic drugs targeting DNA methyltransferases, histone deacetylases, and chromatin remodeling enzymes have shown promise in preclinical and clinical studies, offering potential therapeutic benefits alone or in combination with conventional chemotherapy or immunotherapy.

Furthermore, non-coding RNAs represent attractive targets for cancer therapy, with emerging RNA-based therapeutics showing efficacy in preclinical models (Feng, Prentice et al. 2004, Heyn, Corrêa et al. 2020, Dixit, Chaudhari et al. 2021).

CONCLUSION

In conclusion, cancer epigenomics represents a dynamic and rapidly evolving field that offers profound insights into the molecular underpinnings of cancer. By unraveling the mechanisms governing epigenetic dysregulation and its consequences on gene expression and cellular behavior, researchers are uncovering new opportunities for understanding, diagnosing, and treating cancer. Continued exploration of the intricate interplay between genetics and epigenetics promises to revolutionize our approach to cancer prevention and therapy, ultimately improving outcomes for patients worldwide.

References

1) Aggarwal, B. B. and K. B. Harikumar (2009). "Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases." The international journal of biochemistry & cell biology **41**(1): 40-59.

2) Ahmed, B., et al. (2021). "Adipose tissue and insulin resistance in obese." Biomedicine & Pharmacotherapy **137**: 111315.

3) Alcid, E. A. and T. Tsukiyama (2014). "ATP-dependent chromatin remodeling shapes the long noncoding RNA landscape." Genes & development **28**(21): 2348-2360.

4) Aloufi, N. (2022). Human antigen R (HuR) in the lung: Friend or foe?, McGill University (Canada).

5) Anand, A. V., et al. (2021). "Identification of novel potent pancreatic lipase inhibitors from Ficus racemosa." Biomedicine **41**(1): 23-30.

6) Archetti, D., et al. (2019). "Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease." NeuroImage: Clinical **24**: 101954.

7) Askarian, S., et al. (2023). "The genetic factors contributing to the risk of cleft lip-cleft palate and their clinical utility." Oral and Maxillofacial Surgery **27**(2): 177-186.

8) Asselin, B. and C. Rizzari (2015). "Asparaginase pharmacokinetics and implications of therapeutic drug monitoring." Leukemia & lymphoma **56**(8): 2273-2280.

9) Brüssow, H. (2020). "Problems with the concept of gut microbiota dysbiosis." Microbial biotechnology **13**(2): 423-434.

10) Cao, W., et al. (2012). "EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer." PloS one **7**(12): e52984.

11) Chandraprasad, M. S., et al. (2022). Introduction to cancer and treatment approaches. Paclitaxel, Elsevier**:** 1-27.

12) Chandrasekharan, M. B., et al. (2009). "Ubiquitination of histone H2B regulates chromatin dynamics by enhancing nucleosome stability." Proceedings of the National Academy of Sciences **106**(39): 16686-16691.

13) Conway, J. R., et al. (2019). "Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine." Gut **68**(4): 742-758.

14) Dama, E., et al. (2019). "Deciphering the molecular profile of lung cancer: new strategies for the early detection and prognostic stratification." Journal of clinical medicine **8**(1): 108.

15) Dinant, C., et al. (2008). "Chromatin structure and DNA damage repair." Epigenetics & chromatin **1**: 1-13.

16) Dixit, K., et al. (2021). "Restoration of dysbiotic human gut microbiome for homeostasis." Life Sciences **278**: 119622.

17) Feng, Z., et al. (2004). "Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective." Pharmacogenomics **5**(6): 709-719.

18) Forrest, M. E. and A. M. Khalil (2017). "Regulation of the cancer epigenome by long non-coding RNAs." Cancer letters **407**: 106-112.

19) Hatziapostolou, M. and D. Iliopoulos (2011). "Epigenetic aberrations during oncogenesis." Cellular and Molecular Life Sciences **68**: 1681-1702.

20) Heyn, G. S., et al. (2020). "The impact of adipose tissue–derived miRNAs in metabolic syndrome, obesity, and cancer." Frontiers in endocrinology **11**: 563816.

21) Kulis, M. and M. Esteller (2010). "DNA methylation and cancer." Advances in genetics **70**: 27-56.

22) Maini, R. N., et al. (1998). "Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology **41**(9): 1552-1563.

23) Majid, S., et al. (2010). "MicroRNA-205–directed transcriptional activation of tumor suppressor genes in prostate cancer." Cancer **116**(24): 5637-5649.

24) Skvortsova, K., et al. (2019). "The DNA methylation landscape in cancer." Essays in biochemistry **63**(6): 797-811.

25) Soutschek, M. and G. Schratt (2023). "Non-coding RNA in the wiring and remodeling of neural circuits." Neuron.

26) Statello, L., et al. (2021). "Gene regulation by long non-coding RNAs and its biological functions." Nature reviews Molecular cell biology **22**(2): 96-118.

27) Van Tongelen, A., et al. (2017). "Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes." Cancer letters **396**: 130-137.

28) Yang, J.-J., et al. (2015). "Non-coding RNA-mediated epigenetic regulation of liver fibrosis." Metabolism **64**(11): 1386-1394.